DIVI’S LAB Valuation Report April 2026
Divi’s Laboratories
Founded in 1990 by Dr. Murali K. Divi in Hyderabad, Divi’s Laboratories has evolved into India’s premier API and CDMO (Contract Development & Manufacturing Organisation) franchise. The company operates two large manufacturing complexes — Unit I (Choutuppal, Telangana) and Unit II (Visakhapatnam, Andhra Pradesh) — both certified by the USFDA, EU GMP, Health Canada, and other global agencies, with a third greenfield campus at Kakinada (Unit III) reaching commercial scale in FY26.
The business runs on two primary engines: Generic APIs (contrast media agents, Sartans, carotenoids, nutraceuticals) and Custom Synthesis / CDMO (complex intermediates and APIs for innovator drugs). The CDMO segment now contributes ~54–56% of the product mix after explosive growth over FY25–FY26, up from ~46% in FY24, and is the core re-rating driver. Exports account for ~88% of total revenue, with Europe and North America representing ~73% of the export pie — insulating the business from domestic pricing volatility.
The company’s balance sheet is entirely debt-free, with strong cash generation funding a capex programme exceeding ₹2,000 Cr in FY26, including Kakinada Phase-1 ramp, backward-integration projects, and three new long-term supply commitments. ROCE improved from 15.2% (FY23) to 18.4% (FY25) and is forecast to reach 21%+ by FY27.
A landmark long-term supply agreement signed with a global pharmaceutical major in April 2025, valued at ₹650–750 Cr capex with production commencing January 2027, significantly de-risks the near-term growth path and provides multi-year earnings visibility for the CDMO book.
| Metric (₹ Cr) | FY22 | FY23 | FY24 | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|---|---|
| Net Revenue | 6,969 | 8,960 | 7,770 | 9,360 | 11,653 | 13,190 | 14,740 |
| YoY Growth (%) | — | +28.6% | -13.3% | +20.5% | +24.5% | +13.2% | +11.7% |
| EBITDA | 2,898 | 3,882 | 2,368 | 2,968 | 3,729 | 4,392 | 5,115 |
| EBITDA Margin (%) | 41.6% | 43.3% | 30.5% | 31.7% | 32.0% | 33.3% | 34.7% |
| PAT | 1,894 | 2,541 | 1,600 | 2,191 | 2,778 | 3,285 | 3,839 |
| EPS (₹) | 71.4 | 95.7 | 60.3 | 82.5 | 104.7 | 123.8 | 144.6 |
| P/E (x) | — | — | — | 70.5x | 55.6x | 47.0x | 40.2x |
| EV/EBITDA (x) | — | — | — | 45.6x | 39.1x | 33.0x | 28.1x |
| ROCE (%) | — | — | 15.2% | 18.4% | 20.6% | 21.2% | 21.4% |
| RONW (%) | — | — | 11.6% | 14.3% | 15.9% | 16.3% | 16.4% |
E = Estimates. Source: Company filings, Sharekhan/Mirae Asset estimates, analyst consensus. All values in ₹ Cr unless stated.
The DCF anchors to a 10-year free cash flow projection spanning FY26–FY35, assuming a mid-teens revenue CAGR (driven by CDMO ramp at Kakinada, contrast-media scale-up, and peptide/GLP-1 opportunity), EBITDA margins re-rating from 32% toward 36–38% by FY30 as mix shifts to complex molecules, and steady capex moderating post FY27. The terminal value uses a 5% perpetuity growth rate, reflective of Divi’s dominant positioning in a structurally growing global API outsourcing market. At WACC of 12%, the model yields an intrinsic value of ₹6,800. The analyst price target of ₹7,375 layers in a 51x FY28E EPS multiple — a modest discount to the 65x peak cycle multiple — given near-term generic segment headwinds and a rich starting valuation.
The CMP of ₹5,817 falls squarely within the Accumulate zone, offering ~27% upside to the 12-month target. With the stock having corrected from its 52-week high of ₹7,072 (−17.7%), the risk-reward is asymmetric for patient investors. The ideal strategy is a phased buy: initiate 40–50% allocation at CMP, and add aggressively below ₹5,200 if macro-driven pharma sector selloffs occur. Long-term investors (3–5 year horizon) can tolerate entry as high as ₹6,400 given the compounding potential of the CDMO franchise.
CDMO Momentum
Custom synthesis now at 56% of mix. Pipeline of 12–15 projects with commercial launches expected across FY27–FY28. Long-term supply deal (₹650–750 Cr capex) anchors FY28 earnings base.
Kakinada Unit III
Greenfield campus operational in Q4 FY25. Phase-1 ramp through FY26; Phase-2 triggers depend on new project wins. Estimated to add ₹2,000–2,500 Cr incremental capacity by FY28.
Contrast Media & Sartans
Multi-year volume ramp in iodinated contrast-media APIs as global healthcare demand rises. Sartan product qualification with new European buyers continues.
Peptides / GLP-1
Divi’s is investing in peptide synthesis capabilities targeting the rapidly growing GLP-1 (weight-loss/diabetes) API market. Commercial scale anticipated by FY27–FY28.
Margin Re-rating
EBITDA margins bottomed at 28% in FY24 and are recovering toward 33–35% by FY27 as higher-complexity molecules displace commoditised generics in the revenue mix.
BioSecure Act Tailwind
US BioSecure Act (pending full implementation) positions Indian CDMO players as preferred alternatives to Chinese CMOs. Divi’s regulatory track record makes it a first-choice partner.
The FY26–FY28 revenue CAGR is estimated at 16–18% (consensus: 14–17%), with EPS CAGR of ~20% supported by margin expansion. Exports retain ~88% share; US + Europe ~73% of exports. In constant-currency terms, FY25 growth was 18% — underlying demand is robust even excluding forex tailwinds. Management guided double-digit revenue growth for FY26 with CapEx of ₹2,000+ Cr, funded entirely through internal accruals, maintaining the debt-free balance sheet.
Catalysts (Bull)
Risks (Bear)
| Company | CMP (₹) | Mkt Cap (Cr) | Rev FY25 (Cr) | EBITDA Mgn | P/E (TTM) | EPS (FY25) | ROCE % |
|---|---|---|---|---|---|---|---|
| Divi’s Labs (DIVISLAB) | 5,817 | 1,54,500 | 9,360 | 31.7% | 70.5x | 82.5 | 18.4% |
| Sun Pharma | ~1,700 | 4,07,000 | 56,700 | 28.5% | 38x | ~45 | 22% |
| Cipla | ~1,490 | 1,20,000 | 27,500 | 25.0% | 27x | ~54 | 20% |
| Laurus Labs | ~600 | 32,000 | 5,500 | 20.0% | 55x | ~11 | 12% |
| Syngene International | ~750 | 30,000 | 3,800 | 26.0% | 48x | ~15 | 17% |
| Zydus Lifesciences | ~1,050 | 1,06,000 | 22,000 | 24.0% | 24x | ~44 | 23% |
Peer data approximate. Source: Public filings, Screener, analyst estimates. Highlighted row = Divi’s Laboratories.
Divi’s commands a significant premium to peers on P/E (70x vs. sector average ~35–40x) and EV/EBITDA — justified by its debt-free balance sheet, CDMO franchise moat, regulatory track record, and superior margin profile. Among pure-play API/CDMO names globally, its closest comparable is Lonza or Cambrex (not listed in India), which trade at 20–30x EBITDA on premium quality. The premium will likely be sustained as long as CDMO growth continues to outpace generic segment headwinds.
Verdict: Accumulate with Conviction
Divi’s Laboratories is India’s most irreplaceable API/CDMO franchise — zero debt, global regulatory acceptance, dominant market share in select molecules, and a multi-year growth runway through Kakinada, CDMO expansion, and emergent GLP-1/peptide capabilities. At CMP of ₹5,817, the stock is 17.7% off its 52-week high and trades at ~70x FY25 earnings — expensive on backward-looking metrics, but reasonable when viewed against FY27E P/E of ~47x and a 20%+ EPS CAGR. The near-term risk is generic pricing pressure and CDMO project timing; the medium-term opportunity is category-defining. Accumulate in the ₹5,200–5,800 range in tranches. Target ₹7,375 over 12 months (51x FY28E EPS). Stop-loss: ₹4,800 on a closing basis.
